Clinical trials: Osteoporosis Postmenopausal
Osteoporosis
A Study of LY2541546 in Women With Low Bone Mineral Density
The primary objectives of this study include evaluating the dose response of LY2541546 using bone mineral density (BMD) change from baseline as compared to placebo and evaluating the overall safety and tolerability of LY2541546…
- Trial name
- NCT01144377
- Testing
- LY2541546
- Where
- 8 sites in United States, Denmark and 3 more
- Volunteers
- 154 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Osteoporosis
Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98
RATIONALE: Studying samples of fingernails in the laboratory from patients with breast cancer may help in evaluating bone health in postmenopausal women undergoing hormone therapy for breast cancer.
- Trial name
- NCT00899288
- Testing
- spectroscopy
- Volunteers
- 60 people
- Sponsor
- ETOP IBCSG Partners Foundation
Postmenopausal Osteoporosis
Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.
Dose-response in Japanese patients with postmenopausal osteoporosis.
- Trial name
- NCT00238745
- Testing
- Bazedoxifene
- Volunteers
- 375 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopausal Osteoporosis
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women
This study is designed to provide information about the bone anabolic properties and absorption profile of Unigene's PTH Analog when administered as oral tablets over a period of 24 weeks to postmenopausal women with osteoporosis.
- Trial name
- NCT01321723
- Testing
- PTH analog, Forsteo (Teriparatide)
- Where
- 4 sites in Denmark, Estonia
- Volunteers
- 97 people
- Sponsor
- Unigene Laboratories Inc.
Postmenopausal Osteoporosis
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.
- Trial name
- NCT06079476
- Testing
- Romosozumab
- Where
- 10 sites in India
- Volunteers
- 100 people
- Sponsor
- Amgen
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Post Menopausal Osteoporosis
ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study.
- Trial name
- NCT00545090
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 17 sites in Hong Kong, Indonesia and 3 more
- Volunteers
- 561 people
- Sponsor
- Hoffmann-La Roche
Postmenopausal, Osteopenia
Effects of Denosumab on the Pharmacokinetics of Etanercept
The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis…
- Conditions
- Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
- Trial name
- NCT01294397
- Testing
- Etanercept, Denosumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis
Denosumab of Intas is biosimilar denosumab candidate under development by Intas Pharmaceutical Limited (Biopharma Division). Denosumab of Intas is already approved by Indian drug licensing authority- Drug Controller General…
- Trial name
- NCT05419427
- Testing
- Denosumab, Denosumab-Ref
- Where
- India
- Volunteers
- 552 people
- Sponsor
- Lambda Therapeutic Research Ltd.
Endometrial Hyperplasia, Osteoporosis
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.
- Trial name
- NCT00242710
- Testing
- Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg
- Where
- 9 sites in United States
- Volunteers
- 1,083 people
- Sponsor
- Pfizer
Osteoporosis
Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice
This survey is conducted for preparing application material for re examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, and assessing the safety and efficacy profiles of VIVIANT in usual practice…
- Trial name
- NCT01793142
- Testing
- Viviant
- Where
- 60 sites in South Korea
- Volunteers
- 3,430 people
- Sponsor
- Pfizer
Postmenopausal Osteoporosis
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
This is a multi-center, randomized, open-label, parallel group, study being conducted in the United States and in Europe in postmenopausal women.
- Trial name
- NCT00936897
- Testing
- Ibandronate, Denosumab
- Volunteers
- 833 people
- Sponsor
- Amgen
Osteoporosis
Effects of Proteins Fraction Derived From Milk on Osteoporosis Prevention
Osteoporosis is defined as a systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.
- Trial name
- NCT01478724
- Testing
- Milk proteins fraction
- Where
- France
- Volunteers
- 291 people, healthy volunteers welcome
- Sponsor
- Soredab
Postmenopausal Osteoporosis
A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen
The purpose of this study is to determine which of two delivery methods of Parathyroid Hormone (PTH) is preferred by patients after 14 days of use for each.
- Trial name
- NCT02478879
- Testing
- ZP-PTH, FORTEO
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Zosano Pharma Corporation
Osteoporosis, Postmenopausal, Osteoporosis Fracture
New Biomarkers and Therapeutic Targets in Osteoporosis Via Omics Technologies
This study aims to discover novel biomarkers and therapeutic targets for osteoporosis through the use of advanced omics technologies, including proteomics and metabolomics.
- Conditions
- Osteoporosis, Postmenopausal, Osteoporosis Fracture, Osteoporosis, Severe
- Trial name
- NCT06525688
- Testing
- Bone, Serum and Plasma sample
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- National and Kapodistrian University of Athens
Osteoporosis
Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women
This study will evaluate clinical safety and pharmacokinetics of Maxmarvil® in healthy postmenopausal women
- Trial name
- YY_PK_2011 (NCT01526278)
- Testing
- Maxmarvil®
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Yuyu Pharma, Inc.
Osteoporosis Postmenopausal
Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
To confirm the non-inferiority of 75 mg risedronate tablets taken on 2 consecutive days per month as compared to 5 mg risedronate tablets taken daily in increasing bone mass in lumbar spine in postmenopausal women with…
- Trial name
- NCT00358176
- Testing
- Risedronate (HMR4003)
- Where
- 11 sites in United States, Argentina and 9 more
- Volunteers
- 1,231 people
- Sponsor
- Sanofi
Osteoporosis, Postmenopausal
A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.
- Trial name
- NCT00557310
- Testing
- teriparatide
- Where
- 6 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Primary Hyperparathyroidism, Bone Diseases, Metabolic
Radius Loading in Primary Hyperparathyroidism
The purpose of the study is to determine the effect of forearm exercise on forearm bone density in post-menopausal women with or without primary hyperparathyroidism.
- Conditions
- Primary Hyperparathyroidism, Bone Diseases, Metabolic, Osteoporosis, Postmenopausal, Bone Loss, Postmenopausal
- Trial name
- NCT01571843
- Testing
- Forearm exercise program, Walking program
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Columbia University
Breast Cancer, Osteoporosis
Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer
Bone Mineral Density (BMD) as measured by X-ray shows the amount of calcium in the bone. Low BMD may reflect osteoporosis, a condition where there is an increased risk of fracture.
- Trial name
- NCT00587925
- Testing
- Bone Mineral Density
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center